Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:AVDLNASDAQ:GYRENASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$12.01+3.0%$9.29$4.88▼$19.58$260.57MN/A103,803 shs17,242 shsAVDLAvadel Pharmaceuticals$9.46+0.3%$8.41$6.38▼$17.30$919.02M1.41.24 million shs182,087 shsGYREGyre Therapeutics$8.43+2.5%$8.92$6.11▼$19.00$788.51M1.9118,036 shs123,962 shsPHVSPharvaris$17.38+0.5%$15.50$11.51▼$25.50$908.54M-2.8574,540 shs21,478 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+4.76%+18.74%-9.33%+2.46%+1,165,999,900.00%AVDLAvadel Pharmaceuticals-0.63%+4.08%+8.52%+19.82%-39.78%GYREGyre Therapeutics+7.03%-19.25%-11.23%-26.08%-23.18%PHVSPharvaris+4.79%+9.09%-5.93%+15.28%-2.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals2.1459 of 5 stars3.51.00.00.02.81.70.6GYREGyre Therapeutics0.1373 of 5 stars0.00.00.00.02.51.70.0PHVSPharvaris2.111 of 5 stars3.53.00.00.02.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25168.01% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$19.43104.62% UpsideGYREGyre Therapeutics 3.00BuyN/AN/APHVSPharvaris 3.00Buy$40.67135.34% UpsideCurrent Analyst Ratings BreakdownLatest AARD, AVDL, GYRE, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.003/27/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/11/2025GYREGyre TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/10/2025AARDAardvark TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$29.003/10/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals$194.45M4.72N/AN/A$0.98 per share9.69GYREGyre Therapeutics$100.64M7.79$0.17 per share50.49$0.18 per share46.47PHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals-$160.28M-$0.27N/A158.25N/A-52.53%-93.34%-44.77%8/7/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02421.70∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)PHVSPharvaris-$109.18M-$3.01N/AN/AN/AN/A-38.52%-36.69%8/13/2025 (Estimated)Latest AARD, AVDL, GYRE, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AAVDLAvadel PharmaceuticalsN/A2.972.60GYREGyre TherapeuticsN/A3.723.29PHVSPharvarisN/A19.0819.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AAVDLAvadel Pharmaceuticals69.19%GYREGyre Therapeutics23.99%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AAVDLAvadel Pharmaceuticals4.80%GYREGyre Therapeutics19.52%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AAVDLAvadel Pharmaceuticals7096.74 million91.74 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataPHVSPharvaris3052.29 million46.10 millionNot OptionableAARD, AVDL, GYRE, and PHVS HeadlinesRecent News About These CompaniesPharvaris reports promising results for deucrictibant in HAEJune 3 at 11:28 PM | investing.comPharvaris reports promising results for deucrictibant in HAEJune 3 at 11:28 PM | investing.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?June 3 at 12:39 PM | marketbeat.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2 at 7:41 AM | gurufocus.comPharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock NewsJune 2 at 7:41 AM | gurufocus.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2 at 7:41 AM | gurufocus.comPharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated AngioedemaJune 2 at 7:19 AM | quiverquant.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated AngioedemaJune 2 at 7:00 AM | globenewswire.comPharvaris N.V.: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateJune 1 at 6:55 AM | finanznachrichten.dePharvaris (NASDAQ:PHVS) Shares Up 6.7% - Time to Buy?May 30, 2025 | marketbeat.comWoodline Partners LP Makes New Investment in Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comNorthern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comVR Adviser LLC Has $61.73 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)May 21, 2025 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Pharvaris (PHVS)May 21, 2025 | theglobeandmail.comPharvaris Announces Abstract Acceptance for Presentation at Key Angioedema Congresses in 2025May 19, 2025 | quiverquant.comPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming CongressesMay 19, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Sold by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comPatient Square Capital LP Sells 34,738 Shares of Pharvaris (NASDAQ:PHVS)May 16, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comPharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 TargetMay 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAARD, AVDL, GYRE, and PHVS Company DescriptionsAardvark Therapeutics NASDAQ:AARD$12.01 +0.35 (+3.00%) As of 11:59 AM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Avadel Pharmaceuticals NASDAQ:AVDL$9.46 +0.03 (+0.28%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Gyre Therapeutics NASDAQ:GYRE$8.43 +0.21 (+2.49%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Pharvaris NASDAQ:PHVS$17.38 +0.10 (+0.55%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
